Precision Medicine For Pseudomonas Spurs Polyphor's Swiss IPO Plans
Executive Summary
The Swiss developer of a Phase III potential first-in-class antibiotic for Pseudomonas infections plans to list on the Swiss Stock Exchange, SIX, underlining the unmet need for better drugs for nosocomial pneumonia, and also the upturn in the bourse's popularity for European IPOs.
You may also be interested in...
QIDP Roundup: Familiar Names Dominate 2019 Designations
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
Polyphor's Stock Slides As Murepavadin Trials Are Halted
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.
MedinCell Boosts Funding For Long-Acting Injectables Portfolio
France's long-acting injectables technology company, MedinCell, which is collaborating with Teva on a Phase III long-acting risperidone formulation, has completed an IPO on Euronext Paris, giving a lift to its development plans.